T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer.

TILs immunohistochemistry vulvar squamous cell cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
31 Aug 2022
Historique:
received: 19 06 2022
revised: 25 08 2022
accepted: 25 08 2022
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 10 9 2022
Statut: epublish

Résumé

Background: Although quantification of tumor infiltrating lymphocytes (TILs) has become of increasing interest in immuno-oncology, only little is known about TILs infiltration in the tumor microenvironment and its predictive value in vulvar cancer. Methods: Immunohistochemistry and automated digital image analysis was applied to measure the densities of CD3+ (DAKO, #IR503) and CD8+ (DAKO, #IR623) TILs at the invasive margin and in the center of 530 vulvar squamous cell cancers. Results: An elevated density of CD3+ T-cell at the invasive margin was significantly associated with low tumor stage (p = 0.0012) and prolonged survival (overall survival [OS] p = 0.0027, progression free survival [PFS] p = 0.024) and was independent from tumor stage, nodal stage, grade, and HPV-status in multivariate analysis (p < 0.05). The prognostic impact of CD3+ cells in the center of the tumor was weaker compared to the invasive margin (OS p = 0.046, PFS p = 0.031) and lacking for CD8+ T-cell densities at any location (p ≥ 0.14 each). Unsupervised clustering of CD3+ and CD8+ T-cell densities identified three major subgroups corresponding to the immune desert (137 patients), immune excluded (220 patients) and immune inflamed phenotypes (133 patients). Survival analysis revealed a particular poor prognosis for the immune desert phenotype for OS (p = 0.0071) and PFS (p = 0.0027). Conclusion: Our data demonstrate a high prognostic value of CD3+ T-cells at the invasive margin and immune phenotypes in vulvar squamous cell cancer.

Identifiants

pubmed: 36077784
pii: cancers14174246
doi: 10.3390/cancers14174246
pmc: PMC9454842
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

World J Gastroenterol. 2009 Dec 21;15(47):5898-906
pubmed: 20014453
Int J Gynecol Cancer. 2011 May;21(4):717-21
pubmed: 21543933
Int J Cancer. 2015 Feb 15;136(4):E85-94
pubmed: 25220265
Cancer Immunol Immunother. 2003 Jul;52(7):423-8
pubmed: 12695859
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
J Exp Clin Cancer Res. 2020 May 18;39(1):89
pubmed: 32423420
Br J Cancer. 2018 Jul;119(2):153-159
pubmed: 29955135
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Cancer Treat Res. 2020;180:173-195
pubmed: 32215870
Trends Immunol. 2018 Aug;39(8):632-643
pubmed: 29779848
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Front Med (Lausanne). 2021 Jan 27;8:622330
pubmed: 33585526
Immunity. 2011 Aug 26;35(2):161-8
pubmed: 21867926
Anticancer Res. 2005 May-Jun;25(3B):2027-31
pubmed: 16158940
Elife. 2018 Sep 04;7:
pubmed: 30179157
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Clin Cancer Res. 2019 Jan 1;25(1):125-133
pubmed: 30301825
Cancer Manag Res. 2018 Jan 09;10:61-68
pubmed: 29386916
J Clin Oncol. 2019 Feb 1;37(4):318-327
pubmed: 30557521
Int J Clin Exp Pathol. 2017 Sep 01;10(9):9846-9852
pubmed: 31966872
Int J Cancer. 2015 Feb 15;136(4):E95-106
pubmed: 25220367
Springerplus. 2016 Feb 18;5:125
pubmed: 26933624
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Adv Exp Med Biol. 2017;1036:19-31
pubmed: 29275462
Gynecol Oncol. 2012 Apr;125(1):186-93
pubmed: 22155674
BMC Cancer. 2020 Aug 31;20(1):823
pubmed: 32867707
Breast Cancer Res. 2018 Feb 26;20(1):15
pubmed: 29482642
Immunol Rev. 2017 Mar;276(1):145-164
pubmed: 28258703
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cell. 2018 Aug 9;174(4):968-981.e15
pubmed: 30078711
Front Immunol. 2018 May 03;9:978
pubmed: 29774034
J Cell Physiol. 2019 Jun;234(6):8509-8521
pubmed: 30520029
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
Hum Vaccin Immunother. 2016 Jun 2;12(6):1352-6
pubmed: 26901390
Geburtshilfe Frauenheilkd. 2016 Oct;76(10):1035-1049
pubmed: 27765958
J Natl Cancer Inst. 2015 Jan 24;107(3):
pubmed: 25618900
Am J Reprod Immunol. 2020 Jul;84(1):e13244
pubmed: 32294293
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Cancer Immunol Immunother. 2014 Mar;63(3):297-303
pubmed: 24368339
Gynecol Oncol. 2017 May;145(2):298-304
pubmed: 28236455
Dis Markers. 2019 May 2;2019:2532518
pubmed: 31191745
J Immunother Cancer. 2019 Sep 3;7(1):236
pubmed: 31481117
Oncotarget. 2017 Jul 11;8(28):46204-46210
pubmed: 28515351
Mod Pathol. 2019 Apr;32(4):576-584
pubmed: 30401949
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Virchows Arch. 2020 Jul;477(1):93-102
pubmed: 31993774
Semin Oncol. 2015 Aug;42(4):663-71
pubmed: 26320069
Cancer Immunol Res. 2018 Oct;6(10):1122-1128
pubmed: 30279188
Cancer Med. 2020 Nov;9(22):8333-8344
pubmed: 33047888
J Immunol Res. 2017;2017:6940546
pubmed: 29376081
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Clin Oncol. 2019 Nov 1;37(31):2825-2834
pubmed: 31487218
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023

Auteurs

Eike Burandt (E)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Niclas C Blessin (NC)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Ann-Christin Rolschewski (AC)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Florian Lutz (F)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Tim Mandelkow (T)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Cheng Yang (C)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Elena Bady (E)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Viktor Reiswich (V)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Ronald Simon (R)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Guido Sauter (G)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Sven Mahner (S)

Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.

Nikolaus de Gregorio (N)

Department of Gynecology, University Hospital Ulm, 89070 Ulm, Germany.
Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, 74078 Heilbronn, Germany.

Rüdiger Klapdor (R)

Department of Gynecology and Obesterics, Hannover Medical School, 30625 Hannover, Germany.

Matthias Kalder (M)

Department of Gynecology, Medical Center Philipps University Marburg, 35043 Marburg, Germany.

Elena I Braicu (EI)

European Competence Center Ovarian Cancer, Charité, Campus Virchow Klinikum, Charité-University Hospital, 13353 Berlin, Germany.

Sophie Fürst (S)

Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.

Maximilian Klar (M)

Department of Gynecology, University of Freiburg, 79106 Freiburg im Breisgau, Germany.

Hans-Georg Strauß (HG)

Department Gynecology and Policlinic, University Hospital Martin-Luther-Universität Halle-Wittenberg, 06120 Halle, Germany.

Katharina Prieske (K)

Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Colposcopy Clinic at the Jerusalem Hospital Hamburg, 20357 Hamburg, Germany.
Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.

Linn Wölber (L)

Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Colposcopy Clinic at the Jerusalem Hospital Hamburg, 20357 Hamburg, Germany.

Classifications MeSH